AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in patients with HD. DESIGN: The investigators will include 20 HD mutations carriers and 15 healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 11C-UCB-J PET-CT and 18F-FDG PET-MR at baseline and after 2 years.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
33
Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Baseline differences in synaptic density.
Baseline differences (%) in (regional) synaptic density between patients and controls.
Time frame: Data analysis wel be done when all subjects have undergone the baseline evaluation.
Baseline correlations between clinical scores and regional synaptic density.
Correlations between clinical scores and regional synaptic density in the patient group at baseline.
Time frame: Data analysis wel be done when all subjects have undergone the baseline evaluation.
Differences in the rate of decline of synaptic density.
Differences (%) in the rate of decline of synaptic density between patients and controls.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
Correlations between progression of the clinical scores and decline of synaptic density.
Correlations between progression of the clinical scores and decline of synaptic density in the patient group, after longitudinal follow up of 2 years.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
Baseline differences in cerebral glucose metabolism.
Baseline differences (%) in (regional) glucose metabolism between patients and controls.
Time frame: Data analysis wel be done when all subjects have undergone the baseline evaluation.
Baseline correlations between clinical scores and cerebral glucose metabolism.
Correlations between clinical scores and cerebral glucose metabolism in the patient group at baseline.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
Differences in the rate of decline of cerebral glucose metabolism.
Differences (%) in the rate of decline in cerebral glucose metabolism between patients and controls.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
Correlations between progression of the clinical scores and decline of cerebral glucose metabolism in the patient group, after longitudinal follow up of 2 years.
Correlations between progression of the clinical scores and decline of cerebral glucose metabolism in the patient group, after longitudinal follow up of 2 years.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.